"
Genetic Polymorphisms of Hepatic ABC-Transporter in Patients with Hepatocellular Carcinoma"
written by Minoru Fukuda, Yasutsugu Kawahara, Takeshi Hirota, Setsuko Akizuki, Shigeto Shigeto, Hisato Nakajima, Ichiro Ieiri, Akihiro Ohnishi,
published by
Journal of Cancer Therapy,
Vol.1 No.3, 2010
has been cited by the following article(s):
[1]
|
Prevalence of ABCC3‐1767G/A polymorphism among patients with antiretroviral‐associated hepatotoxicity
|
|
2020 |
|
|
[2]
|
Bile salt export pump, arginase 1, and hepatocyte paraffin 1 expression in differential diagnosis of hepatocellular carcinoma from nonhepatocellular …
|
|
2019 |
|
|
[3]
|
A meta-analysis of MDR1 polymorphisms rs1128503 and rs1045642 and susceptibility to hepatocellular carcinoma
|
|
2019 |
|
|
[4]
|
Charakterizace nových inhibitorů cyklin-dependentních kinas v modelu hepatocelulárního karcinomu
|
|
THESIS,
2018 |
|
|
[5]
|
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study
|
|
Cancer Chemotherapy and Pharmacology,
2017 |
|
|
[6]
|
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer …
|
|
Cancer Chemotherapy and Pharmacology,
2017 |
|
|
[7]
|
INTERACTIONS ENTRE THERAPIES CIBLEES ANTI-ANGIOGÉNIQUES (BEVACIZUMAB, SORAFÉNIB) ET TRANSPORTEURS D'EFFLUX
|
|
Thèse,
2017 |
|
|
[8]
|
Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma
|
|
Tumor Biology,
2015 |
|
|
[9]
|
Polimorfizmi ABC transportera i njihova uloga u tumorskim stanicama
|
|
2014 |
|
|
[10]
|
Targeted inhibition of the FGF 19‐FGFR 4 pathway in hepatocellular carcinoma; translational safety considerations
|
|
Liver International,
2014 |
|
|
[11]
|
Targeted inhibition of the FGF19‐FGFR4 pathway in hepatocellular carcinoma; translational safety considerations
|
|
Liver International,
2014 |
|
|
[12]
|
Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma
|
|
Hepatology,
2013 |
|
|
[1]
|
Prevalence of ABCC3
-1767G/A polymorphism among patients with antiretroviral-associated hepatotoxicity
Molecular Genetics & Genomic Medicine,
2020
DOI:10.1002/mgg3.1124
|
|
|
[2]
|
A meta-analysis of MDR1 polymorphisms rs1128503 and rs1045642 and susceptibility to hepatocellular carcinoma
Journal of International Medical Research,
2019
DOI:10.1177/0300060519855869
|
|
|
[3]
|
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study
Cancer Chemotherapy and Pharmacology,
2017
DOI:10.1007/s00280-017-3268-y
|
|
|
[4]
|
Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma
Tumor Biology,
2015
DOI:10.1007/s13277-015-3407-1
|
|
|
[5]
|
Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations
Liver International,
2014
DOI:10.1111/liv.12462
|
|
|
[6]
|
Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma
Hepatology,
2013
DOI:10.1002/hep.26187
|
|
|